AstraZeneca Spies Success For Antibody To Prevent COVID-19 Infection In Vulnerable

Could Be First With Pre-Exposure Authorization

While it is likely to be fourth to market, AstraZeneca’s long-acting antibody combination could help the US battle SARS-CoV-2 in vaccine-skeptical states, data from study suggests.

AstraZeneca
AstraZeneca's antibody combination, if authorized, will be fourth to market, but could prevent infection in vulnerable populations in whom vaccines are not fully effective, or in the unvaccinated.

AstraZeneca’s long-acting coronavirus antibody combination AZD7442 has scored its first trial success, reducing the risk of developing symptomatic COVID-19 by 77% compared with placebo.

The positive results come from the PROVENT Phase III trial of the antibody combination as a pre-exposure prophylaxis – achieving...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip